Selank: What the Evidence Actually Shows

Selank is marketed as an anxiolytic and nootropic peptide, sold overwhelmingly as a nasal spray. It shares a Russian research lineage with Semax — both trace back to the Institute of Molecular Genetics of the Russian Academy of Sciences — but it is a chemically distinct compound with its own separate discovery paper and its own separate human trial record, not a rebrand of the same molecule.

What it is, and where it comes from

Selank is a synthetic heptapeptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, built as an extended analog of tuftsin — a naturally occurring tetrapeptide fragment of the immunoglobulin IgG heavy chain with known immunomodulatory activity. A 2003 study from the Institute of Pharmacology of the Russian Academy of Medical Sciences tested Selank alongside ten other tuftsin-family peptide compounds in rodent stress-behavior models, reporting "positive emotional effects and antistress actions" tied to each compound's specific molecular structure¹. That mechanistic lineage — tuftsin-family, immunomodulatory-adjacent, anxiolytic rather than neurotrophic — is what actually separates Selank from Semax, whose researched effects center on BDNF upregulation instead.

The human evidence: real, but against an active comparator, not placebo

Two real human studies exist and were read in full for this article, both from the same Russian research group. A 2014 study compared Selank head-to-head against phenazepam, a benzodiazepine, in 60 patients with phobic-anxiety and somatoform disorders, reporting "pronounced anxiolytic and mild nootropic effects" that persisted for a week after the last dose². A 2015 study, indexed by PubMed as a Randomized Controlled Trial, tested a different question: whether adding Selank to phenazepam therapy could reduce the benzodiazepine's own side effects (attention and memory impairment, sedation, sexual disturbances) while speeding its anxiolytic onset — it found that it did, in a 70-patient combined cohort³. Read both plainly for what they are: real, structured human trials with validated psychiatric outcome scales (HDRS, CGI, the Spielberger scale), not case reports — but neither is placebo-controlled. Both compare Selank against or alongside an already-active anxiolytic drug, which this article states precisely rather than describing either as a "placebo-controlled trial."

The regulatory picture — the same discrepancy pattern Semax's own article found

Checked live for this article, Selank's U.S. regulatory status shows the identical pattern this site's Semax article already documented for itself: two FDA documents that do not agree. FDA's current, officially categorized 503A Bulks List — updated May 14, 2026, fetched fresh and text-searched — contains no mention of Selank in Category 1, 2, or 3⁴. FDA's companion descriptive page, "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks," still lists a "Selank acetate (TP-7)" row today, fetched live for this article, stating: "Compounded drugs containing selank acetate may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA lacks important information regarding any safety issues raised by selank acetate administered to humans⁵." One document omits Selank; the other still names it — the same shape of discrepancy, independently re-confirmed for a second compound in this same batch rather than assumed to carry over automatically from Semax's own finding.

The safety signal — fully null, unlike Semax's own thin one

DailyMed's structured-product-label search returns zero results for "selank," confirming no FDA-approved drug product exists under that name⁶. openFDA's FAERS adverse-event database returns zero reports under every naming variant tried for this article — "SELANK," "SELANK ACETATE," and "TP-7"⁷ — a fully null result, distinct from Semax's own 2-report history elsewhere in this corpus. Read that honestly in both directions: it is not evidence of safety, since a compound with no formal reporting channel generates no reports by definition, not because none exist to report.

What this means if you're considering it

None of the 31 providers this site's own reviews cover sell Selank as a primary, boarded product — this site's own identity-layer research confirms it is not tagged to any reviewed seller. Selank is overwhelmingly sold and administered as a nasal spray rather than an injectable — this corpus's own prior research, done while investigating Semax, already found no standalone injectable Selank product in a live vendor check, only a combined Semax/Selank nasal-spray SKU — which is why this site does not carry a Selank reconstitution calculator, the same finding already reached for Semax's own calculator page. Selank's human evidence is real — two structured trials with validated psychiatric outcome scales — but both are active-comparator or add-on designs against an existing benzodiazepine, not placebo-controlled trials. If you're researching Semax specifically, our Semax evidence review covers the other half of this same Russian-neuroscience research lineage, with a genuinely different mechanism (BDNF upregulation) and its own separate, longer human trial history.